AU2017357052B2 - Compositions and methods for treating diabetes, hypertension and hypercholesterolemia - Google Patents

Compositions and methods for treating diabetes, hypertension and hypercholesterolemia Download PDF

Info

Publication number
AU2017357052B2
AU2017357052B2 AU2017357052A AU2017357052A AU2017357052B2 AU 2017357052 B2 AU2017357052 B2 AU 2017357052B2 AU 2017357052 A AU2017357052 A AU 2017357052A AU 2017357052 A AU2017357052 A AU 2017357052A AU 2017357052 B2 AU2017357052 B2 AU 2017357052B2
Authority
AU
Australia
Prior art keywords
amino acid
acid sequence
seq
polypeptide
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017357052A
Other languages
English (en)
Other versions
AU2017357052A1 (en
Inventor
Jonathan POLLETT
Ngoc THAI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imagine Pharma LLC
Original Assignee
Imagine Pharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imagine Pharma LLC filed Critical Imagine Pharma LLC
Publication of AU2017357052A1 publication Critical patent/AU2017357052A1/en
Assigned to IMAGINE PHARMA LLC reassignment IMAGINE PHARMA LLC Amend patent request/document other than specification (104) Assignors: IMAGINE PHARMA
Assigned to Imagine Pharma, LLC. reassignment Imagine Pharma, LLC. Amend patent request/document other than specification (104) Assignors: IMAGINE PHARMA LLC
Assigned to IMAGINE PHARMA, LLC reassignment IMAGINE PHARMA, LLC Amend patent request/document other than specification (104) Assignors: Imagine Pharma, LLC.
Application granted granted Critical
Publication of AU2017357052B2 publication Critical patent/AU2017357052B2/en
Priority to AU2022203741A priority Critical patent/AU2022203741B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2017357052A 2016-11-13 2017-11-13 Compositions and methods for treating diabetes, hypertension and hypercholesterolemia Active AU2017357052B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022203741A AU2022203741B2 (en) 2016-11-13 2022-05-31 Compositions and methods for treating diabetes, hypertension and hypercholesterolemia

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662421332P 2016-11-13 2016-11-13
US62/421,332 2016-11-13
PCT/US2017/061343 WO2018089909A1 (en) 2016-11-13 2017-11-13 Compositions and methods for treating diabetes, hypertension and hypercholesterolemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022203741A Division AU2022203741B2 (en) 2016-11-13 2022-05-31 Compositions and methods for treating diabetes, hypertension and hypercholesterolemia

Publications (2)

Publication Number Publication Date
AU2017357052A1 AU2017357052A1 (en) 2019-05-02
AU2017357052B2 true AU2017357052B2 (en) 2022-03-24

Family

ID=62107069

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017357052A Active AU2017357052B2 (en) 2016-11-13 2017-11-13 Compositions and methods for treating diabetes, hypertension and hypercholesterolemia
AU2022203741A Active AU2022203741B2 (en) 2016-11-13 2022-05-31 Compositions and methods for treating diabetes, hypertension and hypercholesterolemia

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022203741A Active AU2022203741B2 (en) 2016-11-13 2022-05-31 Compositions and methods for treating diabetes, hypertension and hypercholesterolemia

Country Status (9)

Country Link
US (2) US10548941B2 (enExample)
EP (1) EP3538124A4 (enExample)
JP (3) JP2020502056A (enExample)
KR (1) KR102497242B1 (enExample)
CN (1) CN110087666B (enExample)
AU (2) AU2017357052B2 (enExample)
BR (1) BR112019009511A2 (enExample)
MX (1) MX2019005466A (enExample)
WO (1) WO2018089909A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3538124A4 (en) * 2016-11-13 2020-07-22 Imagine Pharma COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES, HYPERTENSION AND HYPERCHOLESTEROLEMIA
BR112020013845A2 (pt) * 2018-01-09 2020-12-01 Imagine Pharma, Llc polipeptídeo ou formulação, métodos para modulação de crescimento celular endotelial e para tratamento de uma doença, e, uso de um polipeptídeo ou formulação.
MX2020014242A (es) * 2018-06-25 2021-05-27 Imagine Pharma Llc Composiciones y métodos para propagar las células de islotes productoras de insulina y usos terapéuticos de las mismas.
CN110974943A (zh) * 2019-12-09 2020-04-10 广东药科大学 一种口服胰岛素药物制剂及其制备方法
CN116685344A (zh) * 2020-12-08 2023-09-01 想象制药有限责任公司 治疗伤口的组合物和方法
AU2022349361A1 (en) * 2021-09-22 2024-03-07 Imagine Pharma Llc Compositions and methods for propogating insulin and glucagon secreting cells from type 1 diabetic pancreatic tissue and therapeutic uses thereof
US20250388638A1 (en) * 2021-12-11 2025-12-25 Imagine Pharma Llc Compositions and methods for oral delivery
WO2025207834A1 (en) * 2024-03-28 2025-10-02 Imagine Pharma Llc Dietary supplements, compositions, and uses thereof for increasing telomerase activity and extending telomere length

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064625A1 (en) * 2001-02-15 2002-08-22 Chondrogenesis Pty Ltd. Matrix gene expression in chondrogenesis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4025395B2 (ja) * 1997-04-09 2007-12-19 花王株式会社 新規ペクチン酸リアーゼ
US20020042062A1 (en) * 1999-09-24 2002-04-11 Mark Stearns Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20050118151A1 (en) * 2001-05-29 2005-06-02 Syddansk Universitet Proteins in diabetes proteome anlysis
WO2003068908A2 (en) * 2001-07-10 2003-08-21 Gene Logic, Inc. Cardiotoxin molecular toxicology modeling
EP2275127B1 (en) * 2002-04-02 2012-09-19 Ben Gurion University Of The Negev Research And Development Authority Protein-based streptococcus pneumoniae vaccines
EP1656155A2 (en) * 2003-06-02 2006-05-17 Ohio University Use of genes differentially expressed during aging of liver for treatment and diagnosis
JP2005245202A (ja) * 2004-03-01 2005-09-15 Japan Science & Technology Agency ヒトＴＦＩＩＥαの新規な亜鉛結合ドメインの構造的特徴および機能
WO2008127813A1 (en) * 2007-03-09 2008-10-23 Hiberna Corporation Hibernation-related genes and proteins, activators and inhibitors thereof and methods of use
WO2010129023A2 (en) * 2009-04-28 2010-11-11 President And Fellows Of Harvard College Supercharged proteins for cell penetration
WO2012054739A2 (en) * 2010-10-21 2012-04-26 New York University Structure-guided identification of binding interactions of human laminin receptor precursor with laminin and identification of compounds that affect binding
CA2817851A1 (en) * 2010-11-12 2012-05-18 The Johns Hopkins University Albumin-bound protein/peptide complex as a biomarker for disease
ES2569185T3 (es) 2011-03-01 2016-05-09 Nucana Biomed Limited Derivados de fosforamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento del cáncer
SG11201602012RA (en) * 2013-09-25 2016-04-28 Pronutria Inc Compositions and formulations for maintaining and increasing muscle mass, strength, and performance and methods of production and use thereof
CN106687128B (zh) * 2014-10-31 2022-05-10 Ngm生物制药有限公司 用于治疗代谢病症的组合物和方法
US20190000923A1 (en) * 2015-12-22 2019-01-03 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP3538124A4 (en) 2016-11-13 2020-07-22 Imagine Pharma COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES, HYPERTENSION AND HYPERCHOLESTEROLEMIA
BR112020013845A2 (pt) * 2018-01-09 2020-12-01 Imagine Pharma, Llc polipeptídeo ou formulação, métodos para modulação de crescimento celular endotelial e para tratamento de uma doença, e, uso de um polipeptídeo ou formulação.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064625A1 (en) * 2001-02-15 2002-08-22 Chondrogenesis Pty Ltd. Matrix gene expression in chondrogenesis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Q. Guo et al. "Discovery of peptidylarginine deiminase-4 substrates by protein array: antagonistic citrullination and methylation of human ribosomal protein S2", Mol. BioSyst. 7: 2286-2295. (Year: 2011). *

Also Published As

Publication number Publication date
US20200222499A1 (en) 2020-07-16
US10751384B2 (en) 2020-08-25
AU2022203741A1 (en) 2022-06-23
US20180133280A1 (en) 2018-05-17
US10548941B2 (en) 2020-02-04
MX2019005466A (es) 2019-10-02
JP7711967B2 (ja) 2025-07-23
WO2018089909A1 (en) 2018-05-17
BR112019009511A2 (pt) 2019-07-30
AU2022203741B2 (en) 2024-02-15
KR20190084070A (ko) 2019-07-15
JP2025163025A (ja) 2025-10-28
CN110087666A (zh) 2019-08-02
EP3538124A1 (en) 2019-09-18
CN110087666B (zh) 2024-04-30
EP3538124A4 (en) 2020-07-22
JP2020502056A (ja) 2020-01-23
JP2023071670A (ja) 2023-05-23
AU2017357052A1 (en) 2019-05-02
CA3041362A1 (en) 2018-05-17
KR102497242B1 (ko) 2023-02-09

Similar Documents

Publication Publication Date Title
AU2022203741B2 (en) Compositions and methods for treating diabetes, hypertension and hypercholesterolemia
US20200353054A1 (en) Use of ave0010 for the treatment of diabetes mellitus type 2
EP3268029B1 (en) Treatment of type 2 diabetes mellitus patients
EP3295952A1 (en) Pharmaceutical formulation comprising glp-1 analogue and preparation method thereof
US20090202494A1 (en) Combined use of glp-1 agonists and gastrin for regulating blood glucose levels
US20110124557A1 (en) Blood sugar-modulating polypeptides
US20080194483A1 (en) GLP-1 (9-36) methods and compositions
US11612637B2 (en) Compositions and methods for treating diabetes, hypertension and hypercholesterolemia
US20230263856A1 (en) Compositions and methods for treating diabetes, hypertension and hypercholesterolemia
CA3041362C (en) Compositions and methods for treating diabetes, hypertension and hypercholesterolemia
WO2010055711A1 (ja) Ｓｉｒｓ患者を救命するためのペプチド組成物
KR101535895B1 (ko) 코프리신 펩타이드 CopA3를 유효성분으로 포함하는 암 질환 예방 및 치료용 약학적 조성물
CN102883737A (zh) Ii型糖尿病的治疗方法
CN111744006A (zh) 一种用于防治糖尿病视网膜病变的药物组合物
CN113727996A (zh) 重组蛋白用于治疗代谢疾病
KR20230163124A (ko) 코로나바이러스 질환의 예방 또는 치료용 조성물
KR20210154309A (ko) 호랑나비 유충으로부터 유래된 펩타이드인 파필리오신-3 및 이의 용도
EP2421547A1 (en) Use of (hexenoyl trans-3)hgrf(1-44)nh2 and ritonavir in combination therapy
HK1185807A (en) Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
HK1185807B (en) Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: IMAGINE PHARMA LLC

Free format text: FORMER NAME(S): IMAGINE PHARMA

HB Alteration of name in register

Owner name: IMAGINE PHARMA, LLC.

Free format text: FORMER NAME(S): IMAGINE PHARMA LLC

HB Alteration of name in register

Owner name: IMAGINE PHARMA, LLC

Free format text: FORMER NAME(S): IMAGINE PHARMA, LLC.

FGA Letters patent sealed or granted (standard patent)